Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Rapamycin is used to prevent graft rejection in transplant recipients based on its ability to suppress T-cell proliferation. The drug blocks the activity of a protein known as mammalian target of ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its ...

Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of ...